nanotech investing Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
nanotech investing Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
nanotech investing Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
nanotech investing Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease
nanotech investing New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference
nanotech investing Longeveron Granted Small or Medium-sized Enterprise Status by the European Medicines Agency
nanotech investing Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
nanotech investing Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
nanotech investing Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome
nanotech investing Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome
Edgewater Wireless Reports Fiscal 2026 Year-End Results and Highlights Growing Semiconductor Execution and Industry Validation
Silver Hammer and Stroud Resources Announce Updated Mineral Resource Estimate for the Santo Domingo Silver-Gold Project, Mexico
